Neurofibromatosis type 1: Piecing the puzzle together

Canadian Journal of Neurological Sciences

Volumn 25, Issue 3, 1998, Pages 181-191

  Feldkamp, Matthias M ^a,b   Gutmann, David H ^c   Guha, Abhijit ^a,b,d,e,f  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; GENE PRODUCT; GUANOSINE TRIPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE; NEUROFIBROMIN; RAS PROTEIN;

AUTOSOMAL DOMINANT DISORDER; CLINICAL FEATURE; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR CLONING; NEUROFIBROMA; NEUROFIBROMATOSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0031870437     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100033990     Document Type: Review

References (142)

1. von Recklinghausen FD. Über die multiplen Fibrome der Haut und ihre Beziehung zu den multiplen Neuromen. Berlin, Hirschwald, 1882.
2. Riccardi VM, Eichner JE. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. Baltimore, MD, Johns Hopkins University Press, 1992.
3. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993; 72: 791-800.
4. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane organizing protein causes neurofibromatosis type 2. Nature 1993; 363: 515-521.
5. Evans DGR, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992; 84: 603-618.
6. Tibbles JAR, Cohen MM. The Proteus syndrome: the Elephant Man diagnosed. Br Med J 1986; 293: 683-685.
7. Lott IT, Richardson Jr EP. Neuropathological findings and the biology of neurofibromatosis. Adv Neurol 1981; 29: 23-32.
8. Gutmann DH, Collins FS. von Recklinghausen neurofibromatosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. von Recklinghausen Neurofibromatosis, New York, McGraw-Hill, 1995: 677-696.
9. Burwell RG, James NJ, Johnston DI. Cafe-au-lait spots in schoolchildren. Arch Dis Child 1982; 57: 631-632.
10. Stumpf S, Alksne JF, Annegers JF et al. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988; 45: 575-578.
11. Huson SM. Neurofibromatosis 1: A clinical and genetic overview. In: Huson SM, Hughes RAC, eds. Neurofibromatosis 1: A clinical and genetic overview. London, Chapman and Hall, 1994: 160-203.
12. Grifa A, Piemontese MR, Melchionda S, et al. Screening of neurofibromatosis type 1 gene: identification of a large deletion and of an intronic variant. Clin Genet 1995; 47: 281-284.
13. Sorensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med 1986; 314: 1010-1015.
14. Zoller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Göteborg, Sweden. Acta Derm Venereol 1995; 75: 136-140.
15. Riccardi VM. Von Recklinghausen neurofibromatosis. N Engl J Med 1981; 305: 1617-1627.
16. Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994; 330: 597-601.
17. Mulvihill JJ. Malignancy: epidemiologically associated cancers. In: Huson SM, Hughes RAC, eds. Malignancy: Epidemiologically Associated Cancers. London, Chapman & Hall Medical, 1994: 305-315.
18. Marchuk DA, Saulino AM, Tavakkol R, et al. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics 1991; 11: 931-940.
19. Preiser SA, Davenport CB. Multiple neurofibromatosis (von Recklinghausen disease) and its inheritance. Am J Med Sci 1918; 156: 507.
20. Crowe F. A Clinical, Pathological and Genetic Study of Multiple Neurofibromatosis. Springfield, IL, C.C. Thomas, 1956.
21. Borberg A. Clinical and genetic investigations into tuberous sclerosis and Recklinghausen's neurofibromatosis. Acta Psychiatr Neurol (Suppl.) 1951; 71: 1-239.
22. Riccardi VM, Lewis RA. Penetrance of von Recklinghausen neurofibromatosis: a distinction between predecessors and descendents. Am J Hum Genet 1988; 42: 284-289.
23. Sergeyev AS. On the mutation rate of neurofibromatosis. Humangenetik 1975; 28: 129-138.
24. Carey JC, Baty BJ, Johnson JP, et al. The genetic aspects of neurofibromatosis. Ann N Y Acad Sci 1986; 486: 45-56.
25. Monaco AP, Neve RL, Colletti-Feener C, et al. Isolation of candidate cDNAs for portions of the Duschenne muscular dystrophy gene. Nature 1986; 323: 646-650.
26. Richards FM, Payne SJ, Zbar B, et al. Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene. Hum Mol Genet 1995; 4: 2139-2143.
27. Rodenhiser DI, Coulter-Mackie MB, Singh SM. Evidence of DNA methylation in the neurofibromatosis type 1 (NF1) gene region of 17q11.2. Hum Mol Genet 1993; 2: 439-444.
28. Colman SD, Williams CA, Wallace MR. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat Genet 1995; 11: 90-92.
29. Jadayel D, Fain P, Upadhyaya M, et al. Paternal origin of new mutations in von Recklinghausen neurofibromatosis. Nature 1990; 343: 558-559.
30. Hall JG. Genomic imprinting: review and relevance to human diseases. Am J Hum Genet 1990; 46: 857-873.
31. Stephens K, Kayes L, Riccardi VM, et al. Preferential mutation of the neurofibromatosis type 1 gene in paternally derived chromosomes. Hum Genet 1992; 88: 279-282.
32. Monk M, Boubelik M, Lehnert S. Temporal and regional changes in DNA methylation in the embryonic, extraembryonic and germ line lineages during mouse embryo development. Development 1987; 99:371-382.
33. Driscoll DJ, Migeon BR. Sex difference in methylation of single-copy genes in human meiotic germ cells: implications for X chromosome inactivation, parental imprinting, and origin of CpG mutations. Somat Cell Mol Genet 1990; 16: 267-282.
34. Miller M, Hall JG. Possible maternal effect on severity of neurofibromatosis. Lancet 1978; 2: 1071-1073.
35. Easton DF, Ponder MA, Huson SM, Ponder BAJ. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet 1993; 53: 305-313.
36. Sarfarazi M, Huson SM, Edwards JH. An exclusion map for von Recklinghausen neurofibromatosis. J Med Genet 1987; 24: 515-520.
37. Barker D, Wright E, Nguyen K, et al. Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science 1987; 236: 1100-1102.
38. Stephens K, Green P, Riccardi VM, et al. Genetic analysis of eight loci tightly linked to neurofibromatosis 1. Am J Hum Genet 1989; 44: 13-19.
39. Goldgar DE, Green P, Parry DM, Mulvihill JJ. Multipoint linkage analysis in neurofibromatosis type 1: an international collaboration. Am J Hum Genet 1989; 44: 6-12.
40. Ledbetter DH, Rich DC, O'Connell P, Leppert M, Carey JC. Precise localization of NF1 to 17q11.2 by balanced translocation. Am J Med Genet 1989; 44: 20-24.
41. Schmidt MA, Michels VV, Dewald GW. Cases of neurofibromatosis with rearrangements of chromosome 17 involving band 17q11.2. Am J Med Genet 1987; 28: 771-777.
42. O'Connell P, Leach R, Cawthon RM, et al. Two NF1 translocations map within a 600-kilobase segment of 17q11.2. Science 1989; 244: 1087-1088.
43. Fountain JW, Wallace MR, Bruce MA, et al. Physical mapping of a translocation breakpoint in neurofibromatosis. Science 1989; 244: 1085-1087.
44. O'Connell P, Viskochil D, Buchberg AM, et al. The human homolog of murine Evi-2 lies between two von Recklinghausen neurofibromatosis translocations. Genomics 1990; 7: 547-554.
45. Cawthon RM, Anderson LB, Buchberg AM, et al. cDNA sequence and genomic structure of EV12B, a gene lying within an intron of the neurofibromatosis type 1 gene. Genomics 1991; 9: 446-460.
46. Viskochil D, Cawthon R, O'Connell P, et al. The gene encoding the oligodendrocyte-myelin glycoprotein is embedded within the neurofibromatosis type 1 gene. Mol Cell Biol 1991; 11: 906-912.
47. Xu GF, O'Connell P, Viskochil D, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990; 62: 599-608.
48. Viskochil D, Buchberg AM, Xu G, et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990; 62: 187-192.
49. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990; 249: 181-186.
50. Li Y, O'Connell P, Breidenbach HH, et al. Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics 1995; 25: 9-18.
51. Hajra A, Martin-Gallardo A, Tarle SA, Freedman M, Wilson-Gunn S, et al. DNA sequences in the promoter region of the NF1 gene are highly conserved between human and mouse. Genomics 1994; 21: 649-652.
52. Viskochil D, White R, Cawthon R. The neurofibromatosis type 1 gene. Ann Rev Neurosci 1993; 16: 183-205.
53. DeClue JE, Cohen BD, Lowy DR. Identification and characterization of the neurofibromatosis type1 protein product. Proc Natl Acad Sci U S A 1991; 88: 9914-9918.
54. Gutmann DH, Wood DL, Collins FS. Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci U S A 1991; 88: 9658-9662.
55. Daston MM, Scrable H, Nordlund M, et al. The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron 1992; 8: 415-428.
56. Gutmann DH, Geist RT, Wright DE, Snider WD. Expression of the neurofibromatosis 1 (NF1) isoforms in developing and adult rat tissues. Cell Growth Differ 1995; 6: 315-323.
57. Andersen LB, Ballester R, Marchuk DA, et al. A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity. Mol Cell Biol 1993; 13: 487-495.
58. Bernards A, Haase VH, Murthy AE, et al. Complete human NF1 cDNA sequence: two alternatively spliced mRNAs and absence of expression in a neuroblastoma line. DNA Cell Biol 1992; 11: 727-734.
59. Teinturier C, Danglot G, Slim R, et al. The neurofibromatosis 1 gene transcripts expressed in peripheral nerve and neurofibromas bear the additional exon located in the GAP domain. Biochem Biophys Res Commun 1992; 188: 851-857.
60. Gutmann DH, Andersen LB, Cole JL, Swaroop M, Collins FS. An alternatively-spliced mRNA in the carboxy terminus of the neurofibromatosis type 1 (NF1) gene is expressed in muscle. Hum Mol Genet 1993; 2: 989-992.
61. Gutmann DH, Geist RT, Rose K, Wright DE. Expression of two new protein isoforms of the neurofibromatosis type 1 gene product, neurofibromin, in muscle tissues. Dev Dyn 1995; 202: 302-311.
62. Danglot G, Regnier V, Fauvet D, et al. Neurofibromatosis 1 (NF1) mRNAs expressed in the central nervous system are differentially spliced in the 5′ part of the gene. Hum Mol Genet 1995; 4: 915-920.
63. Geist RT, Gutmann DH. Expression of a developmentally-regulated neuron-specific isoform of the neurofibromatosis 1 (NF1.) gene. Neurosci Lett 1996; 211: 85-88.
64. Platten M, Giordano MJ, Dirven CMF, Gutmann DH, Louis DN. Up-fegulation of specific NF1 gene transcripts in sporadic pilocytic astrocytomas. Am J Pathol 1996; 149: 621-627.
65. Buchberg AM, Cleveland LS, Jenkins NA, Copeland NG. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature 1990; 347: 291-294.
66. GAP and neurofibromin. J Biol Chem 1996; 271: 16409-16415.
67. Cullen PJ, Hsuan JJ, Truong O, et al. Identification of a specific Ins(1,3,4,5)P4-binding protein as a member of the GAPI family. Nature 1995; 376: 527-530.
68. Bollag G, McCormick F. Differential regulation of rasGAP and neurofibromatosis gene product activities. Nature 1991; 351: 576-579.
69. Downward J. Regulation of p21ras by GTPase activating proteins and guanine nucleotide exchange proteins. Curr Opin Genet Dev 1992; 2: 13-18.
70. Downward J. Regulatory mechanisms for ras proteins. Bioessays 1992; 14: 177-184.
71. McCormick F. Signal transduction. How receptors turn Ras on. Nature 1993; 363: 15-16.
72. McCormick F. Ras signaling and NF1. Curr Opin Genet Dev 1995; 5: 51-55.
73. Guha A, Lau N, Gutmann D, et al. Ras-GTP levels are elevated in human NF1 peripheral nerve tumours. Oncogene 1996; 12: 507-513.
74. Maekawa M, Li S, Iwamatsu A, et al. A novel mammalian Ras GTPase-activating protein which has phospholipid-binding and Btk homology regions. Mol Cell Biol 1994; 14: 6879-6885.
75. Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature 1993; 363: 83-85.
76. Lowenstein EJ, Daly RJ, Batzer AG, et al. The SH2 and SH3 domain-containing protein GRB2 links receptors tyrosine kinases to ras signaling. Cell 1992; 70: 431-442.
77. Buday L, Downward J. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 1993; 73: 611-620.
78. Chardin P, Camonis JH, Gale NW, et al. Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science 1993; 260: 1338-1343.
79. Egan SE, Giddings BW, Brooks MW, et al. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature 1993; 363: 45-51.
80. Li W, Nishimura R, Kashishian A, et al. A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase. Mol Cell Biol 1994; 14: 509-517.
81. Rozakis-Adcock M, McGlade J, Mbamalu G, et al. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature 1992; 360: 689-692.
82. Bos JL. Ras oncogenes in human cancers: a review. Cancer Res 1989; 49: 4682-4689.
83. Cantley LC, Auger KR, Carpenter C, et al. Oncogenes and signal transduction. Cell 1991; 64: 281-302.
84. Martin GA, Viskochil D, Bollag G, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990; 63: 843-849.
85. Ballester R, Marchuk D, Boguski M, et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 1990; 63: 851-859.
86. Xu GF, Lin B, Tanaka K, et al. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 1990; 63: 835-841.
87. Nur-E-Kamal MSA, Varga M, Maruta H. The GTPase-activating NF1 fragment of 91 amino acids reverses v-Ha-Ras-induced malignant phenotype. J Biol Chem 1993; 268: 22331-22337.
88. Basu TN, Gutmann DH, Fletcher JA, et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992; 356: 713-715.
89. ras contributes to malignant tumor growth in von Recklinghausen (type1) neurofibromatosis. Cell 1992; 69: 265-273.
90. Johnson MR, DeClue JE, Felzmann S, et al. Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function. Mol Cell Biol 1994; 14: 641-645.
91. Nakafuku M, Nagamine M, Ohtoshi A, et al. Suppression of oncogenic Ras by mutant neurofibromatosis type 1 genes with single amino acid substitutions. Proc Natl Acad Sci U S A 1993; 90: 6706-6710.
92. Feldkamp MM, Lau N, Provias JP, Guha A. Acute presentation of a neurogenic sarcoma in a patient with neurofibromatosis type 1: A pathologic and molecular explanation. J Neurosurg 1996; 84; 867-873.
93. Johnson MR, Look AT, DeClue JE, Valentine MB, Lowy DR. Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP·Ras. Proc Natl Acad Sci U S A 1993; 90: 5539-5543.
94. Li Y, White R. Suppression of a human colon cancer cell line by introduction of an exogenous NF1 gene. Cancer Res 1996; 56: 2872-2876.
95. Gutmann DH. Tumor suppressor genes as negative growth regulators in development and differentiation. Int J Dev Biol 1995; 39: 895-907.
96. Gregory PE, Gutmann DH, Mitchell A, et al. The neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules. Somat Cell Mol Genet 1993; 19: 265-274.
97. Bollag G, McCormick F, Clark R. Characterization of full-length neurofibromin: tubulin inhibits Ras GAP activity. EMBO J 1993; 12: 1923-1927.
98. Boyer MJ, Gutmann DH, Collins FS, Bar-Sagi D. Crosslinking of the surface immunoglobulin receptor in B lymphocytes induces a redistribution of neurofibromin but not p120-GAP. Oncogene 1994; 9: 349-357.
99. Izawa I, Tamaki N, Saya H. Phosphorylation of neurofibromatosis type 1 gene product (neurofibromin) by cAMP-dependent protein kinase. FEBS Lett 1996; 382: 53-59.
100. Gutmann DH, Collins FS. The neurofibromatosis type 1 gene and its protein product, neurofibromin. Neuron 1993; 10: 335-343.
101. Gutmann DH, Mahadeo DK, Giordano M, Silbergeld D, Guha A. Increased neurofibromatosis 1 gene expression in astrocytic tumors: positive regulation by p21-ras. Oncogene 1996; 12: 2121-2127.
102. Giordano MJ, Mahadeo DK, He YY, et al. Increased expression of the neurofibromatosis 1 (NF1) gene product, neurofibromin, in astrocytes in response to cerebral ischemia. J Neurosci Res 1996; 43: 246-253.
103. Knudson Jr AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971; 68: 820-823.
104. Xu W, Mulligan LM, Ponder MA,et al. Loss of NF1 alleles in phaeochromocytomas from patients with type I neurofibromatosis. Genes Chromosomes Cancer 1992; 4: 337-342.
105. Gutmann DH, Cole JL, Stone WJ, Ponder BAJ, Collins FS. Loss of neurofibromin in adrenal gland tumors from patients with neurofibromatosis type 1. Genes Chromosomes Cancer 1994; 10: 55-58.
106. Sawada Si, Florell S, Purandare SM, et al. Identification of NF1 mutations in both alleles of a dermal neurofibroma. Nat Genet 1996; 14: 110-112.
107. Takahashi K, Suzuki H, Hatori M, et al. Reduced expression of neurofibromin in the soft tissue tumours obtained from patients with neurofibromatosis type I. Clin Sci 1995; 88: 581-585.
108. Legius E, Marchuk DA, Collins FS, Glover TW. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 1993; 3: 122-126.
109. Jacks T, Shin TS, Schmitt EM, et al. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 1994; 7: 353-361.
110. Brannan CI, Perkins AS, Vogel KS, et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 1994; 8: 1019-1029.
111. Kirby ML, Gale TF, Stewart DE. Neural crest cells contribute to aorticopulmonary septation. Science 1983; 220: 1059-1061.
112. Vogel KS, Brannan CI, Jenkins NA, Copeland NG, Parada LF. Loss of neurofibromin results in neurotrophin-independent survival of embryonic sensory and sympathetic neurons. Cell 1995; 82: 733-742.
113. Borasio GD, John J, Wittinghofer A, et al. ras p21 protein promotes survival and fiber outgrowth of cultured embryonic neurons. Neuron 1989; 2: 1087-1096.
114. Kim HA, Rosenbaum T, Marchionni MA, Ratner N, DeClue JE. Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes. Oncogene 1995; 11: 325-335.
115. Rosenbaum C, Krasnoselski AL, Marchionni MA, Brackenbury RW, Ratner N. Neuregulins and neu/erbB2 are required for response of Schwann cells to multiple growth factors. J Neurochem 1996; 66: S47.
116. Johnson MD, Kamso-Pratt J, Federspiel CF, Whetsell Jr. WO. Mast cell and lymphoreticular infiltrates in neurofibromas. Comparison with nerve sheath tumors. Arch Pathol Lab Med 1989; 113: 1263-1270.
117. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57: 2006-2021.
118. Birch R. Peripheral nerve tumors. In: Dyck PJ, Thomas RK, eds. Peripheral Nerve Tumors. Philadelphia, W.B. Saunders, 1993: 1623-1640.
119. Enneking W. Musculo-skeletal Tumor Surgery. Edinburgh, Churchill Livingstone, 1983.
120. Castresana JS, Barrios C, Gomez L, Kreicbergs A. No association between c-myc amplification and TP53 mutation in sarcoma tumorigenesis. Cancer Genet Cytogenet 1994; 76: 47-49.
121. Andreassen A, Oyjord T, Hovig E, et al. p53 abnormalities in different subtypes of human sarcomas. Cancer Res 1993; 53: 468-471.
122. Lothe RA, Slettan A, Saeter G, Bet al. Alterations at chromosome 17 loci in peripheral nerve sheath tumors. J Neuropathol Exp Neurol 1995; 54: 65-73.
123. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994; 54: 794-799.
124. Legius E, Dierick H, Wu R, et al. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer 1994; 10: 250-255.
125. Menon AG, Anderson KM, Riccardi VM, et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A 1990; 87: 5435-5439.
126. Friend SH, Horowitz JM, Gerber MR, et al. Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc Natl Acad Sci U S A 1987; 84: 9059-9063.
127. Wunder JS, Czitrom AA, Kandel R, Andrulis IL. Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas. J Natl Cancer Inst 1991; 83: 194-200.
128. Cance WG, Brennan MF, Dudas ME, Huang CM, Cordon-Cardo C. Altered expression of the retinoblastosis gene product in human sarcomas. N Engl J Med 1990; 323: 1457-1462.
129. Jhanwar SC, Chen Q, Li FP, Brennan MF, Woodruff JM. Cytogenetic analysis of soft tissue sarcomas. Recurrent chromosome abnormalities in malignant peripheral nerve sheath tumors (MPNST). Cancer Genet Cytogenet 1994; 78: 138-144.
130. Ottini L, Esposito DL, Richetta A, et al. Alterations of microsatellites in neurofibromas of von Recklinghausen's disease. Cancer Res 1995; 55: 5677-5680.
131. Uchida T, Wang C, Wada C, et al. Microsatellite instability in transitional cell carcinoma of the urinary tract and its relationship to clinicopathological variables and smoking. Int J Cancer 1996; 69: 142-145.
132. Zhu J, Guo SZ, Beggs AH, et al. Microsatellite instability analysis of primary human brain tumors. Oncogene 1996; 12: 1417-1423.
133. Upadhyaya M, Shen M, Cherryson A, et al. Analysis of mutations at the neurofibromatosis 1 (NF1) locus. Hum Mol Genet 1992; 1: 735-740.
134. Lazaro C, Kruyer H, Gaona A, Estivill X. Two further cases of mutation R1947X in the NF1 gene: screening for a relatively common recurrent mutation. Hum Genet 1995; 96: 361-363.
135. Hofman KJ, Boehm CD. Familial neurofibromatosis type 1: clinical experience with DNA testing. J Pediatr 1992; 120: 394-398.
136. Dublin S, Riccardi VM, Stephens K. Methods for rapid detection of a recurrent nonsense mutation and documentation of phenotypic features in neurofibromatosis type 1 patients. Hum Mutat 1995; 5: 81-85.
137. Gasparini P, D'Agruma L, Pio de Cillis G, et al. Scanning the first part of the neurofibromatosis type 1 gene by RNA- SSCP: identification of three novel mutations and of two new polymorphisms. Hum Genet 1996; 97: 492-495.
138. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994; 77: 175-178.
139. Hancock JF, Paterson H, Marshall CJ. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 1990; 63: 133-139.
140. Kohl NE, Omer CA, Conner MW, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995; 1: 792-797.
141. Yan N, Ricca C, Fletcher J, et al. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype. Cancer Res 1995; 55: 3569-3575.
142. Pang L, Sawada T, Decker SJ, Saltiel AR. Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem 1995; 270: 13585-13588.